Automated Antibody De Novo Sequencing and Its Utility in Biopharmaceutical Discovery.

Authors

K Ilker Sen
Wilfred H Tang
Shruti Nayak
Yong J Kil
Marshall Bern
Berk Ozoglu
Beatrix Ueberheide
Darryl Davis
Christopher Becker

Publication/Presentation Date

5-1-2017

Abstract

Applications of antibody de novo sequencing in the biopharmaceutical industry range from the discovery of new antibody drug candidates to identifying reagents for research and determining the primary structure of innovator products for biosimilar development. When murine, phage display, or patient-derived monoclonal antibodies against a target of interest are available, but the cDNA or the original cell line is not, de novo protein sequencing is required to humanize and recombinantly express these antibodies, followed by in vitro and in vivo testing for functional validation. Availability of fully automated software tools for monoclonal antibody de novo sequencing enables efficient and routine analysis. Here, we present a novel method to automatically de novo sequence antibodies using mass spectrometry and the Supernovo software. The robustness of the algorithm is demonstrated through a series of stress tests. Graphical Abstract ᅟ.

Volume

28

Issue

5

First Page

803

Last Page

810

ISSN

1879-1123

Published In/Presented At

Sen, K. I., Tang, W. H., Nayak, S., Kil, Y. J., Bern, M., Ozoglu, B., Ueberheide, B., Davis, D., & Becker, C. (2017). Automated Antibody De Novo Sequencing and Its Utility in Biopharmaceutical Discovery. Journal of the American Society for Mass Spectrometry, 28(5), 803–810. https://doi.org/10.1007/s13361-016-1580-0

Disciplines

Medical Education | Medicine and Health Sciences

PubMedID

28105549

Department(s)

USF-LVHN SELECT Program, USF-LVHN SELECT Program Students

Document Type

Article